Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 5 Issue 12

Discovery of Diosgenin as Potent and Selective Inhibitors Against Human Carboxylesterase 2

Xiao-Dong Li1,2,a, Hong-Hong Ma2,a, Jun-Qing Gao1, Yi-Shu Zhao2, Xing-Kai Qian2, Guang-Bo Ge2, Li-Wei Zou2,a*, Zong-Jun Liu1,a* and Ling Yang2

1Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

2Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China

aThese Authors have Contributed Equally to this Work

*Corresponding Author: Li-Wei Zou, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China and Zong-Jun Liu, Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Received: November 02, 2021; Published: November 18, 2021


Paris polyphylla Smith var. yunnanensis (Franch.) Hand.-Mazz. has the effects of clearing away heat and toxin, relieving swelling and pain, cooling the liver, and calming convulsion. Human carboxylesterase 2 (hCES2A), one of the most principal drug-metabolizing enzymes, catalyzes the hydrolysis of a variety of endogenous esters and environmental toxicants. In this study, the inhibitory effects against hCES2A of four active ingredients of Paris Polyphylla were assayed using diacetylfluorescein (FD) as a specific optical substrate for hCES2A. Among the four compounds, diosgenin displayed significantly inhibitory activity against hCES2A. Further investigations demonstrate that diosgenin exhibits strong hCES2A inhibition selectivity over other human serine hydrolases, including hCES1A, dipeptidyl peptidase IV (DPP-IV), butyrylcholinesterase (BChE), pancreatic lipase (PL), and thrombin. According to its inhibition kinetic result, diosgenin was a mixed model type inhibitor, and Ki was 1.15 μM. Molecular docking showed that diosgenin could dock well to the active site and Z site of hCES2A, and the hydrophobic interactions might be the major ways for the binding of diosgenin on hCES2A. All results indicated that diosgenin is a potent and selective hCES2A inhibitor, which may potentially affect the metabolism of endogenous substances or cause unpredictable DDI by inhibiting the activity of hCES2A.

Keywords : Paris Polyphylla; Diosgenin; Human Carboxylesterase 2; Inhibitor; Molecular Docking Simulations


  1. Bachovchin D A and B F Cravatt. "The Pharmacological Landscape and Therapeutic Potential of Serine Hydrolases”. Nature Reviews Drug Discovery 1 (2012): 52-68.
  2. Bencharit, S., et al. "Structural Basis of Heroin and Cocaine Metabolism by a Promiscuous Human Drug-Processing Enzyme”. Nature Structural and Molecular Biology5 (2003): 349-356.
  3. Feng F F., et al. "Inhibitory Effects of Polyphyllins I and Vii on Human Cisplatin-Resistant Nsclc Via P53 Upregulation and Cip2a/Akt/Mtor Signaling Axis Inhibition”. Chinese Journal of Natural Medicines 10 (2019): 768-777.
  4. Gupta D D., et al. "Evaluation of Antioxidant, Anti-Inflammatory and Anticancer Activities of Diosgenin Enriched Paris Polyphylla Rhizome Extract of Indian Himalayan Landraces”. Journal of Ethnopharmacology 270 (2021): 113842.
  5. Hatfield M J., et al. "Modulation of Esterified Drug Metabolism by Tanshinones from Salvia Miltiorrhiza ("Danshen")”. Journal of Natural Products 1 (2013): 36-44.
  6. Hosokawa, M. "Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs”. Molecules2 (2008): 412-431.
  7. Hu Q., et al. "Inhibition of Pancreatic Lipase by Environmental Xenoestrogens”. Ecotoxicology and Environmental Safety 192 (2020): 110305.
  8. Huo P C., et al. "Design, Synthesis and Biological Evaluation of Indanone-Chalcone Hybrids as Potent and Selective Hces2a Inhibitors”. European Journal of Medicinal Chemistry 209 (2021): 112856.
  9. Lam S W., et al. "The Role of Pharmacogenetics in Capecitabine Efficacy and Toxicity”. Cancer Treatment Reviews 50 (2016): 9-22.
  10. Lee M S., et al. "Effects of Polyphyllin D, a Steroidal Saponin in Paris Polyphylla, in Growth Inhibition of Human Breast Cancer Cells and in Xenograft”. Cancer Biology and Therapy 11 (2005): 1248-1254.
  11. Li Y G., et al. "Fructus Psoraleae Contains Natural Compounds with Potent Inhibitory Effects Towards Human Carboxylesterase 2”. Fitoterapia 101 (2015): 99-106.
  12. Liu Y J., et al. "Identification and Characterization of Naturally Occurring Inhibitors against Human Carboxylesterase 2 in White Mulberry Root-Bark”. Fitoterapia 115 (2016): 57-63.
  13. Long J Z and B F Cravatt. "The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease”. Chemical Review10 (2011): 6022-6063.
  14. Oh J., et al. "The Novel Carboxylesterase 1 Variant C.662a>G May Decrease the Bioactivation of Oseltamivir in Humans”. PLoS One4 (2017): e0176320.
  15. Quinney SK., et al. "Hydrolysis of Capecitabine to 5'-Deoxy-5-Fluorocytidine by Human Carboxylesterases and Inhibition by Loperamide”. Journal of Pharmacology and Experimental Therapeutics 3 (2005): 1011-1016.
  16. Ren JL., et al. "Traditional Chinese Medicine for Covid-19 Treatment”. Pharmacology Research 155 (2020): 104743.
  17. Ribelles, N., et al. "A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression”. Current Drug Metabolism 4 (2008): 336-343.
  18. Sanghani S P., et al. "Human Carboxylesterases: An Update on Ces1, Ces2 and Ces3”. Protein and Peptide Letters10 (2009): 1207-1214.
  19. Sethi, G., et al. "Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review”. Nutrients 5 (2018).
  20. Shaojun, C., et al. "Expression of Topoisomerase 1 and Carboxylesterase 2 Correlates with Irinotecan Treatment Response in Metastatic Colorectal Cancer”. Cancer Biology and Therapy 3 (2018): 153-159.
  21. Smith N F., et al. "Pharmacogenetics of Irinotecan Metabolism and Transport: An Update”. Toxicology In Vitro2 (2006): 163-175.
  22. Song C., et al. "Polyphyllin Vii Suppresses Cell Proliferation, the Cell Cycle and Cell Migration in Colorectal Cancer”. Oncology Letter1 (2021): 25.
  23. Song SS., et al. "Flavonoids as Human Carboxylesterase 2 Inhibitors: Inhibition Potentials and Molecular Docking Simulations”. International Journal of Biological Macromolecules 131 (2019): 201-208.
  24. Teng J F., et al. "Polyphyllin Vi Induces Caspase-1-Mediated Pyroptosis Via the Induction of Ros/Nf-Κb/Nlrp3/Gsdmd Signal Axis in Non-Small Cell Lung Cancer”. Cancers (Basel)1 (2020).
  25. Tian Y., et al. "Anti-Cancer Effects of Polyphyllin I: An Update in 5 Years”. Chemico-Biological Interactions 316 (2020): 108936.
  26. Trott O and A J Olson. "Autodock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading”. Journal of Computational Chemistry 2 (2010): 455-461.
  27. Wang DD., et al. "Recent Progress in the Discovery of Natural Inhibitors against Human Carboxylesterases”. Fitoterapia 117 (2017): 84-95.
  28. Wang D., et al. "Human Carboxylesterases: A Comprehensive Review”. Acta Pharmaceutica Sinica B 5 (2018): 699-712.
  29. Wang Y Q., et al. "Nevadensin Is a Naturally Occurring Selective Inhibitor of Human Carboxylesterase 1”. International Journal of Biological Macromolecules Pt B (2018): 1944-1954.
  30. Wong C C., et al. "Carboxylesterases 1 and 2 Hydrolyze Phospho-Nonsteroidal Anti-Inflammatory Drugs: Relevance to Their Pharmacological Activity”. Journal of Pharmacology and Experimental Therapeutics 2 (2012): 422-432.
  31. Xing Q., et al. "Efficacy and Safety of Integrated Traditional Chinese Medicine and Western Medicine on the Treatment of Rheumatoid Arthritis: A Meta-Analysis”. Evidence-Based Complementary and Alternative Medicine 2020 (2020): 4348709.
  32. Xu J., et al. "Potential Pharmacokinetic Herb-Drug Interactions: Have We Overlooked the Importance of Human Carboxylesterases 1 and 2?" Current Drug Metabolism 2 (2019): 130-137.
  33. Yang, D., et al. "Human Carboxylesterases Hce1 and Hce2: Ontogenic Expression, Inter-Individual Variability and Differential Hydrolysis of Oseltamivir, Aspirin, Deltamethrin and Permethrin”. Biochemistry and Pharmacology2 (2009): 238-247.
  34. Yano H., et al. "Overexpression of Carboxylesterase-2 Results in Enhanced Efficacy of Topoisomerase I Inhibitor, Irinotecan (Cpt-11), for Multiple Myeloma”. Cancer Science11 (2008): 2309-2314.
  35. Zhang H F., et al. "Inhibitory Effects of Polyphyllin Vii on the Migration and Invasion of Colon Cancer Cells and the Mechanism”. Immunological Journal004 (2018): 286-293.
  36. Zhang J., et al. "A High-Throughput Screening Assay for Dipeptidyl Peptidase-Iv Inhibitors Using Human Plasma”. Annals of Methods (2021).
  37. Zhang, J., et al. "A Review of Behcet's Disease from the Perspectives of Both Western and Chinese Medicine”. Journal of Traditional Chinese Medical Sciences 1 (2019): 139-152.
  38. Zhao Y S., et al. "Discovery of Natural Alkaloids as Potent and Selective Inhibitors against Human Carboxylesterase 2”. Bioorganic Chemistry 105 (2020): 104367.
  39. Zou L W., et al. "Carboxylesterase Inhibitors: An Update”. Current Medicinal Chemistry14 (2018): 1627-1649.
  40. Zou L W., et al. "Design, Synthesis, and Structure-Activity Relationship Study of Glycyrrhetinic Acid Derivatives as Potent and Selective Inhibitors against Human Carboxylesterase 2”. European Journal of Medicinal Chemistry 112 (2016): 280-288.
  41. Zou L W., et al. "A Highly Specific Ratiometric Two-Photon Fluorescent Probe to Detect Dipeptidyl Peptidase Iv in Plasma and Living Systems”. Biosensors and Bioelectronics 90 (2017): 283-289.


Citation: Xiao-Dong Li., et al. “Discovery of Diosgenin as Potent and Selective Inhibitors Against Human Carboxylesterase 2". Acta Scientific Medical Sciences 5.12 (2021): 112-121.


Copyright: © 2021 Xiao-Dong Li., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US